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Background
The first episode of psychosis is a critical period in the emer-
gence of cardiometabolic risk.
Aims
We set out to explore the influence of individual and lifestyle
factors on cardiometabolic outcomes in early psychosis.
Method
This was a prospective cohort study of 293 UK adults presenting
with first-episode psychosis investigating the influence of
sociodemographics, lifestyle (physical activity, sedentary
behaviour, nutrition, smoking, alcohol, substance use) and
medication on cardiometabolic outcomes over the following 12
months.
Results
Rates of obesity and glucose dysregulation rose from 17.8% and
12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little
changewas seen over time in the 76.8% tobacco smoking rate or
the quarter who were sedentary for over 10 h daily. We found no
association between lifestyle at baseline or type of antipsychotic
medication prescribed with either baseline or 1-year cardiome-
tabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3
mmol/mol in participants from Black and minority ethnic (BME)
groups, with little change observed in their White counterparts.
At 12 months, one-third of those with BME heritage exceeded
the threshold for prediabetes (HbA1c >39 mmol/mol).
Conclusions
Unhealthy lifestyle choices are prevalent in early psychosis and
cardiometabolic risk worsens over the next year, creating an
important window for prevention. We found no evidence,
however, that preventative strategies should be preferentially
directed based on lifestyle habits. Further work is needed to
determinewhether clinical strategies should allow for differential
patterns of emergence of cardiometabolic risk in people of dif-
ferent ethnicities.
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People with psychotic illnesses die prematurely, mostly from natural
causes, with markedly raised standardised mortality ratios for car-
diovascular disease (CVD, 3.6, 95% CI 3.5–3.6), with young adults
(4.5, 95% CI 4.1–4.8), women (4.6, 95% CI, 4.5–4.7) and people
of White ethnicity (4.9, 95% CI, 4.8–5.0) especially at risk.1
Cardiometabolic dysregulation is evident even from the early
stages of psychosis2 and increases in the months after first presen-
tation, with olanzapine having the most marked effect.3 Clozapine
also affects metabolism, with 55% exhibiting glucose dysregulation
within 3 months of starting.4 A recent meta-analysis reported that
antipsychotics were associated with greater weight gain in Asian
as opposed to Western studies, although very few studies looked
directly at the effects of ethnicity.5 Evidence is needed to determine
whether or not interventions to modify cardiometabolic risk can be
targeted in first-episode psychosis (FEP). Few studies have investi-
gated whether health behaviours at presentation including diet,
physical activity and substance use predict subsequent deterioration
in cardiometabolic status. An exception is a recent prospective study
of 101 people with FEP6 that found that low aerobic fitness was a
significant risk factor for metabolic syndrome. Overall, however,
insufficient prospective observational studies have attempted to dis-
entangle the impact of lifestyle on the emergence of cardiometabolic
risk to reliably inform the development and targeting of effective
preventative strategies.
The main aims of this study were therefore to (a) to determine
the prevalence of cardiometabolic risk factors in an ethnically
diverse population at first presentation with psychosis; (b) to
describe the emergence of additional cardiometabolic risk over
* These authors contributed equally to the work as first authors.
† These authors contributed equally to the work as last authors.
‡ Members of the IMPACT team are listed in the Acknowledgements.
The British Journal of Psychiatry (2019)
Page 1 of 8. doi: 10.1192/bjp.2019.159
1
the year following first presentation with psychosis and (c) to deter-
mine the relationship between lifestyle factors (diet, sedentary
behaviour, smoking, substance use) and antipsychotic medication,
in particular olanzapine and clozapine use, on cardiometabolic
risk both at baseline and at 12-month follow-up. We hypothesised
that there would be an association between baseline lifestyle
choices and (a) cardiometabolic risk at baseline and (b) prospect-
ively in change in cardiometabolic risk over a 1-year follow-up
period. We also hypothesised that the emergence of glucose and
lipid dysregulation would be greater in those prescribed the diben-
zodiazepines, clozapine or olanzapine, compared with other
antipsychotics.
Method
Setting and design
A prospective observational cohort of people was followed up for 12
months after their first presentation with psychosis. The study took
place in in-patient and early intervention in psychosis community
mental health teams in three English mental health National
Health Service (NHS) services.
Eligibility criteria
Inclusion criteria were as follows: (a) aged between 16 and 65 years;
(b) within 6 months of first presentation with psychosis (ICD-10
codes F20–29 and F30–33);7 (c) proficient in English with no
requirement for an interpreter. Patients were excluded if they
were pregnant or had a major medical illness or neurological
disease; had been diagnosed with a severe intellectual disability;
had an organic cause for their psychosis; or had previous contact
with health services for the presence of psychosis. All participants
were included in the study only after giving written, confirmed
consent. The study protocol was approved by the Joint South
London and Maudsley and the Institute of Psychiatry NHS
Research Ethics Committee (08/H0807/53).
Assessments
Patients were assessed at baseline and after 12 months.
Sociodemographic data were recorded at baseline, namely age,
gender, ethnicity (self-report) and years of education. The oper-
ational criteria checklist for psychotic and affective illness
(OPCRIT) was used to assess type of mental health state over the
lifetime.8 All other measures were recorded at both time points.
Selected clinical measures unaffected by fasting state (weight,
blood pressure, haemoglobin A1c (HbA1c), cholesterol, high-
density lipoprotein (HDL)) were recorded where available and uti-
lised in analyses at baseline if the relevant measure post-dated the
onset of psychosis and preceded the research measures, being thus
less likely to have been affected by the introduction of psychotropic
medication. Follow-up clinical measures were utilised if research
measures for that period were missing.
Psychopathology
Mental health status was measured using the Positive and Negative
Symptom Scale,9 Global Assessment of Functioning,10 Clinical
Global Impression Scale,11 Calgary Depression score,12 and the
Young Mania Rating Scale.13
Pharmacological history
Type(s) (British National Formulary definitions) of psychotropic
medication and duration of antipsychotic (in days) were retrospect-
ively extracted from electronic medical records.
Cardiometabolic measures
Metabolic measures comprised anthropometric measures of weight,
height, body mass index (BMI), waist circumference and blood
pressure, as well as fasting blood samples for glucose, glycated
haemoglobin (HbA1c), lipids and C-reactive protein (CRP).
Standardised techniques were used to measure height, blood pres-
sure and weight. Where available, the blood pressure values are
the second blood pressure measurements (first reading presented
in 75/219 participants at baseline; and 39/147 at 12 months).
Waist circumference was measured at the umbilicus with the
patient standing.
Obesity was defined by the World Health Organization
(WHO)14 reference standard (BMI ≥30 kg/m2) and overweight as
BMI ≥25 kg/m2. Diabetes was diagnosed based on a HbA1c of
≥48 mmol/mol (≥6.5%), or a fasting glucose ≥7.0 mmol/L or a
prior diagnosis of diabetes. In keeping with recent guidance
from the American Diabetes Association, an HbA1c of 39–47
mmol/mol (5.7–6.4%) was taken to indicate glucose dysregulation
or a high risk of diabetes.15 The International Diabetes Federation
definitions of other cardiometabolic risk factors were used.16
Insulin resistance was presented using the homeostasis model
assessment – insulin resistance (HOMA-IR), calculated from
fasting glucose and insulin levels. Inflammation was estimated
using high-sensitivity CRP as a marker.
Physical activity and dietary intake
Physical activity was assessed by the International Physical Activity
Questionnaire,17 which has been validated in psychosis.18 The self-
report Dietary Instrument for Nutrition Education (DINE)19 was
used to assess dietary patterns over the previous week. Additional
questions were included to account for sugar intake, the consump-
tion of take-away food, carbonated drinks and adding either salt or
sugar to food/drinks.
Substance use
Cigarette and tobacco consumption were measured using the
Nicotine Dependence questionnaire20 and alcohol use with the
Alcohol Use Disorders Identification Test (AUDIT),21 where
scores of eight or more indicate hazardous and harmful alcohol
use. A modified Cannabis Experience Questionnaire (CEQ-4) was
used to enquire about lifetime and current use of substances22,23
and a urine drug screen requested.
Statistical analysis
Descriptive data are presented in tabular form. Pairwise compari-
sons were done using t-tests for continuous and χ2 tests for categor-
ical outcomes. Baseline associations between continuous scores for
lifestyle and cardiometabolic factors were investigated using
unadjusted and adjusted linear regression models. To account for
different patterns of missingness, we used multiple imputation by
chained equations prior to these analyses, using the lifestyle
factors (DINE saturated fat score, AUDIT hazardous drinking
score, number of h sitting per day and whether taking olanzapine),
cardiometabolic factors (cholesterol, diastolic blood pressure,
HbA1c, waist circumference, BMI, HDL and triglycerides), age,
gender, ethnicity and pre-baseline number of days on antipsychotic
medication in the multiple imputation model. We used the ‘mi
impute chained’ command in Stata version 15.1, with 50 imputed
data-sets for each multiple imputation model. Binary variables
were imputed using logistic regression, using augmented logistic
regression where perfect prediction was detected.24 Continuous
variables were imputed using linear regression unless they appeared
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non-normal, in which case the predictive mean matching imput-
ation method, drawing from five nearest neighbours, was used.25
Imputed data-sets were then used to examine cross-sectional
associations between each lifestyle factor and cardiometabolic
factor separately using linear regression, unadjusted and adjusted
for prespecified potential confounders of CVD risk, namely age,
gender, ethnicity and pre-baseline number of days on antipsychotic
medication. We further explored the cross-sectional associations
between use of dibenzodiazepine medications (yes/no) prior to
baseline and cardiometabolic factors at baseline using the same
model and potential confounders.
For each outcome (change in cardiometabolic factor) at 12
months we employed separate multiple imputation models (using
the same method as above) using the outcome and the same vari-
ables at baseline. We then explored for each baseline lifestyle
factor, separately, whether they were associated with change in
cardiometabolic factors over the 12-month follow-up period,
unadjusted, and then adjusted for the above potential confounders,
investigating associations between use of dibenzodiazepine medica-
tions between baseline and 12 months (yes/no) and cardiometabolic
factors in the same way.
We separately assessed whether cardiometabolic factors at base-
line differed between (a) participants taking medication with less or
greater than 14 days of antipsychotic medication prior to baseline
and (b) participants who were taking medication and those who
were unmedicated prior to baseline.
To account for multiple testing a stricter alpha of 0.01 was pre-
specified as the significance level.26 Tests with a P-value between
0.01 and 0.05 were discussed as a trend and conclusions should be
treated as explorative. Sensitivity analyses were carried out for all
the analyses using complete cases from the full data-set, and also
using a reduced data-set (with only participants with <5 variables
of interest missing) prior to using multiple imputation to check
the extent to which the original multiple imputation was plausible.
Results
We screened 11 705 people for eligibility; 971 were eligible of whom
321 (33.1%) consented to participate (263 declined, 50 transferred,
337 uncontactable). Twenty-eight were excluded after consent when
further information became available, leaving 293 eligible people,
(mean age 30.6 years (s.d. = 10.5)) in the study at baseline, 46.4%
of whom were of White ethnicity; 36.9% Black and 7.8% Asian.
Sixteen withdrew at baseline, and 251 completed baseline measures
with 26 remaining in the study but missing or declining data collec-
tion at that time point. A further 10 participants withdrew during
the study, 1 died and 140 dropped out (51 uncontactable, 73
declined, 11 missed and 5 in prison), with 125 completing 12-
month follow-up assessments. Demographic and clinical character-
istics are reported in supplementary Table 1 available at https://doi.
org/10.1192/bjp.2019.159.
Twelve-month follow-up was completed for 125 patients with
additional selected anthropometric and blood measures taken
from clinical records where available and required. There were no
differences in baseline demographics or cardiometabolic measures
between those who had 12-month follow-up assessments (n =
125) and those who did not (n = 168) (supplementary Table 4).
Cardiometabolic and lifestyle factors in the year
following onset of psychosis
Rates of obesity, hypertriglyceridaemia, diabetes, raised CRP and
low HDL cholesterol all rose over the first year of illness, and the
proportion of people with HbA1c in the glucose dysregulation
range almost doubled (Tables 1 and 2, supplementary Tables 2
and 7 and Fig. 1) Rates of tobacco smoking were high (Tables
2 and 3); smokers consumed a median of ten cigarettes per day,
with little change over time. Combining both self-report and
urinary drug screen data, 49.5% (102/206) of participants were
current users of cannabis at baseline, and 23/183 (12.6%) reported
current usage of ‘other recreational drugs’. The corresponding
figures at 12 months were 38.1% (40/105) and 12/102 (11.8%),
respectively. From baseline to 12 months, 12 (11.3%) participants
initiated cannabis use while 16 (15.5%) stopped using cannabis.
Data were available on antipsychotic prescriptions prior to
baseline for 242 (82.6%) participants. In total 22% (54/242) were
antipsychotic-free before baseline, and a further 65 (26.9%) had
received antipsychotics for less than 2 weeks. The median duration
of antipsychotic treatment for those prescribed antipsychotics pre-
baseline was 21 days (interquartile range (IQR)=9.0–55.5 days)
(mean 43.3 days (s.d.) = 53.3), with most (94.7%; n = 178/188) pre-
scribed second-generation antipsychotics. Overall, 128 people were
prescribed olanzapine across the year, 102 as their first anti-
psychotic. Of those on olanzapine at baseline (n = 89; median
dose 10 mg (IQR = 10–75; range 2.5–25)), 71% (52/73) remained
on olanzapine at follow-up.
At follow-up, 66 people were prescribed olanzapine (we had
dose data of 45 people), at a median dose of 12.5 mg (n = 45, IQR
= 10–17.5; range 2.5–30). All bar 15 had been prescribed anti-
psychotic medication over the course of the study, for a median
of 378 (IQR = 302–434) days (mean of 354.6 (s.d. = 138.9) days),
with those receiving olanzapine prescribed it for a median of 236
(IQR = 61–388) days (mean of 239.6 (s.d. = 169.8) days). No
patients were prescribed clozapine. We did not have data on
somatic medications prescribed over the course of the follow-up.
Participants takingmedication prior to baseline had higher base-
line average waist circumferences (+7.7 cm, 95% CI 2.0–13.4; P =
0.009) compared with those unmedicated. Those who had received
over 2 weeks antipsychotic medication prior to baseline had higher
total cholesterol (+0.5 mmol/L, 95% CI 0.1–0.8; P = 0.007) than
those prescribed antipsychotics for less than 2 weeks (excluding
those prescribed no antipsychotic) (supplementary Table 3).
At baseline, 57% consumed a carbonated drink daily, half
(50%) drinking more than one 500 mL bottle per day and 21.4%
of the total sample drank diet carbonated drinks daily. Three-
quarters (75.7%) consumed tea on a daily basis, most (90.8%)
drinking more than one cup, with 44% of the sample adding 2 teas-
poons or more of sugar to each cup of tea. Salt was added to food
during cooking by 66.5% of participants. A total of 78.5% con-
sumed take-away meals, three-quarters of whom (75.8%) did so
more than once weekly.
Relationship between lifestyle/medication and
cardiometabolic outcomes at baseline and 12-month
follow-up.
Baseline DINE fat scores, sedentary behaviour, AUDIT scores and
pre-baseline olanzapine use were not significantly associated with
any of the baseline cardiometabolic outcomes either unadjusted or
after adjusting for potential confounders (supplementary Table 6).
Nor did the linear regression models show any association
between baseline lifestyle factors and change in any of the cardiome-
tabolic outcomes over 12 months either unadjusted or after adjust-
ing for potential confounders (Table 4). Nor was there evidence of a
difference in change in cardiometabolic outcomes by 12 months in
those participants prescribed olanzapine between baseline and 12
months and those not prescribed olanzapine (unadjusted and
adjusted) (Table 4).
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Sensitivity analyses using complete cases only gave similar
results with no evidence of any associations. Sensitivity analyses
using a reduced data-set prior to imputing also gave similar results.
Effects of gender and ethnicity
Rates of central obesity at baseline were higher in women (62.7%,
n = 37/59) than in men (35.3%, n = 36/102), (χ2 = 11.34, P = 0.001),
with a trend towards women from Black and minority ethnic
(BME) groups having larger waists than their White counterparts
(t = 2.37, P = 0.02), this gap increasing over time in the paired
sample subgroup (supplementary Table 5). White men overall
gained a mean of 4.9 cm in waist circumference over the year,
whereas men from BME groups gained 1.6 cm (Table 3), with
similar findings in the paired sample subgroup (supplementary
Table 5). There was no relationship between ethnicity and BMI.
There was a trend towards lower total cholesterol at 12 months
(P = 0.04) in BME patients.
Although HbA1c levels at baseline were comparable, BME
patients exhibited a significant increase in median HbA1c levels
over 12 months (P<0.01), rising by 3.3 mmol/mol. In contrast, no
change was evident in White patients (Table 3). Where only com-
plete paired data-sets were included in the analysis, median
HbA1c rose in White patients by 1.1 mm/mol and by 3.3 mmol/mol
in participants from BME groups (supplementary Table 5). HbA1c
levels above 39 mmol/mol were seen in 10% (4/40) of White partici-
pants and 34% (18/53) of those from BME groups at 12 months.
There was no significant difference in ethnicity between those
prescribed olanzapine and those not prescribed it (χ2(3) = –3.10,
P = 0.376).
Discussion
This comprehensive large-scale cohort study of patients with FEP
prospectively considers the relationship between lifestyle factors,
medication and cardiometabolic trajectories. Weight gain is the
most obvious problem for many patients both cosmetically and
for their health – here 17.8% were obese at onset, rising to 23.7%
within 1 year. A case has recently been made for obesity to be recog-
nised as a chronic disease27 to allow the preventative strategies
needed at a population level; in psychosis, the rapidity of weight
gain over the first year offers an unrivalled opportunity for preven-
tion, with diet, exercise and medication being key targets. We noted
high consumption of saturated fat, carbonated, high-sugar drinks,
sweetened beverages and added salt. Calorie intake was further aug-
mented by alcohol use (Table 2). Although neither fat intake nor
alcohol use in the early weeks of psychosis predicted longer-term
outcomes in our population, the Keeping the Body in Mind pro-
gramme has successfully worked with dieticians and exercise phy-
siologists to prevent weight gain using lifestyle interventions for
all early in the disease process.28
We also found early emergence of glucose dysregulation; by
1 year twice as many people had HbA1c levels at or above the
American Diabetes Association glucose dysregulation range
(Tables 1 and 2). Diabetes is highly predictive of cardiometabolic
disease and can have an especially significant impact on health in
Table 1 Descriptives at each time point
Baseline 12 months
n Mean s.d./IQR n Mean s.d./IQR
Waist circumference (cm), men 102 90.2 12.1 66 93.4 13.7
Waist circumference (cm), women 59 88.8 16.1 44 89.8 16.8
Systolic blood pressure (mm/Hg) 219 117.4 15.6 147 118.4 15.6
Diastolic blood pressure (mm/Hg) 219 75.0 12.0 147 77.4 12.0
Cholesterol (mmol/L) 186 4.8 1.0 114 4.8 1.1
High density lipoprotein (mmol/L) 179 1.4 0.4 110 1.3 0.4
Triglycerides (mmol/L) 175 1.4 0.9 100 1.3 0.9
Height (cm), men 126 176.6 7.9 – – –
Height (cm), women 68 165.5 7.7 – – –
Weight (kg), men 123 80.0 15.7 66 86.0 17.6
Weight (kg), women 64 71.3 19.4 43 73.2 19.3
BMI (kg/m2), men 119 25.5 4.6 57 27.2 5.3
BMI (kg/m2), women 61 26.0 6.3 36 26.6 5.4
HbA1c (mmol/mol) 167 35.5 7.1 93 37.7 8.3
Fasting glucose (mmol/L) 173 4.8 0.9 95 5.1 1.9
C-reactive protein (mg/L)a 168 1 0.3–2.6 93 1.5 0.5–3.5
Insulin (mU/L)a 125 10.1 5.2–15.3 60 8.8 5.0–14.6
HOMA IRa,b 121 2.1 1.2–3.2 57 1.8 1.0–2.7
AUDIT hazardous drinking score 199 9.4 9.5 115 5.8 6.9
DINE fat intake score 186 32.8 13.5 114 30.7 13.2
IPAQ, mean h sitting per day 178 8.1 4.2 110 8.3 4.2
PANSS total scorec 190 58.2 15.0 114 51.0 15.6
GAF symptoms score 175 51.3 20.5 116 62.9 17.5
GAF disability score 174 56.6 18.1 115 64.8 17.8
CGI severity scale scorea 198 3 2–4 116 2 1–4
CGI improvement scale scorea – – – 111 1 0–2
Calgary Depression Scale total scorea,c 187 4 1–9 118 3 1–8
YMRS scorea,c 185 4 2–8 117 2 0–5
s.d., standard deviation; IQR, interquartile range; BMI, body mass index; HbA1c, haemoglobin A1c; HOMA IR, homeostasis model assessment – insulin resistance; AUDIT, Alcohol Use
Disorders Identification Test; DINE, Dietary Instrument for Nutrition Education; IPAQ, International Physical Activity Questionnaire; PANSS, Positive and Negative Symptom Scale; GAF, Global
Assessment of Functioning; CGI, Clinical Global Impression Scale; YMRS, Young Mania Rating Scale.
a. Medians and upper/lower quartiles presented instead of means standard deviations because of skewed data.
b. Values of fasting glucose over 11 mmol/L were excluded from the calculation of HOMA IR.
c. PANSS, Calgary and YMRS totals were calculated even where individual items were missing (although PANSS was considered missing if any of the three subscale totals, positive
symptoms, negative symptoms and general psychopathology were entirely missing).
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people with psychosis, given the other practical challenges they may
face.
There was a remarkably high baseline prevalence of tobacco
smoking of 76.8%. Smoking confers an almost fivefold risk of mor-
tality in people with schizophrenia.29 Further, nicotine dependence
after psychosis onset predicts both poor medication adherence and
non-remission of psychosis.30 It is therefore worrisome that we saw
little reduction in smoking rates over time. Since this work was com-
pleted, many UK mental health hospitals have become smoke-free
environments31 and although a recent trial has demonstrated that
smoking cessation can be achieved in the community, work
remains to be done to sustain quitting.32 Rates of current cannabis
use and lifetime use of other substances were high, in keeping with
previous work.22
People with psychosis engage in low levels of physical activity.33
Although physical activity at baseline did not predict cardiometa-
bolic outcome in our study, by 12 months 40% of the participants
were engaging in the 150 min of physical activity per week recom-
mended by the WHO (2014).34 Worryingly however, sedentary
behaviour changed little and CRP levels increased over time.
Sedentary behaviour is associated with inflammation in psychosis,35
and inflammation is in turn linked to cardiometabolic disease.36
Both exercise and sedentary behaviour are important targets for
health promotion with studies underway to examine ways of chan-
ging patterns of behaviour in clinical settings.37
Our regression analyses revealed no relationship between
cardiometabolic outcomes and lifestyle, nor any effect of dibenzo-
diazepine medication, despite the high risk of weight gain demon-
strated with olanzapine in other settings.3 A high proportion were
prescribed olanzapine as a first antipsychotic, a practice now not
recommended.38 Of note, no participants were prescribed clozapine
in the first year of their illness, in keeping with the reportedmean lag
time to starting clozapine of 47.7 months (s.d. = 49.7).39 The omis-
sion of clozapine is noteworthy as 23% of people presenting with
their first episode of psychosis are treatment resistant from illness
onset.40
Our sensitivity analyses illustrated the rapidity of cardiometa-
bolic change in early psychosis; those exposed to antipsychotic
medication for more than 14 days before baseline had higher chol-
esterol levels than those on antipsychotics for less than a fortnight,
and those exposed to any antipsychotic medication had a larger
waist circumference at baseline than did individuals who were anti-
psychotic naive.
Effects of ethnicity and gender
Men of White ethnicity appeared to have a particular vulnerability
to emergence of central obesity, increasing their mean waist size
by 4.9 cm, whereas men of other ethnicities gained a more modest
1.6 cm. These changes are clinically significant and the variation
between ethnic groups was in keeping with findings in established
psychosis.41 Central obesity is a better predictor of CVD risk than
is general obesity,42 so this may relate to the lower hazard ratios
seen for all-cause mortality in Black African, Black Caribbean and
South Asian patients with severe mental illness compared with
their White British counterparts.43
Women were at risk of central obesity throughout, with 72.7%
in that category by 1 year, again consistent with the local figure of
95% seen in women with established psychosis.41 Central adiposity
in women is predictive of all-cause mortality inWhite, but not Black
women.44
Minority ethnic groups appeared vulnerable to emergent glucose
dysregulation, with highly clinically relevant increases in median
HbA1c of 3.3 mmol/mol (Table 3 and supplementary Table 5), but
no change seen in White patients. Within the non-diabetic range,
this reflects a highly clinically significant shift in glycaemia in the
BME group, with one-third exceeding the American Diabetes
Association HbA1c threshold for pre-diabetes
15 (>39 mmol/mol
(5.7%)), although it is useful to note that some would not have
been identified as at risk by current National Institute for Health
and Care Excellence guidelines.45 This change in glucose regulation
in a relatively young population over just 1 year highlights the risk of
accelerated emergence of diabetes in people of ethnicities other than
White, and is in keeping with a recent large cross-sectional analysis
of London primary care46 data that showed a three- to tenfold rela-
tive risk of type 2 diabetes in young people with severemental illness.
Strengths and limitations
This is to our knowledge the most comprehensive study to date
examining the effects of lifestyle choice on emergent cardiometabolic
risk. In conducting this study, we recruited an incident sample of
people presenting to both in-patient and community services for
the first time with psychosis and we followed them up for 1 year,
thereby capturing the period with the greatest change in physical
Table 2 Rates of identified cardiometabolic and lifestyle risk factors at
each time point
Baseline 12 months
n % n %
Body mass index (BMI, kg/m2)
BMI ≤25 90 50.0 39 41.9
BMI >25 and ≤30 58 32.2 32 34.4
BMI >30 32 17.8 22 23.7
High total cholesterol (>5 mmol/L)
Yes 76 40.9 46 40.4
No 110 58.1 68 59.6
Raised triglycerides (≥1.7 mmol/L)
Yes 47 26.9 34 34.0
No 128 73.1 66 66.0
Low high-density lipoprotein cholesterola
Yes 46 25.7 37 33.6
No 133 74.3 73 66.4
Type 2 diabetes
Yes 6 3.4 5 5.0
No 172 96.6 94 95.0
HbA1c ≥39 mmol/mol
Yes 20 12.0 22 23.7
No 147 88.0 71 76.3
C-reactive protein
>3 mg/L 37 22.0 28 30.1
≤3 mg/L 131 78.0 65 69.9
Hypertension
Yes 33 15.1 23 15.7
No 186 84.9 124 84.3
IPAQ sitting hours
≤6 h per day 76 42.7 44 40.0
>6 and ≤10 h per day 53 29.8 37 33.6
>10 h per day 49 27.5 29 26.4
Minutes of moderate or vigorous exercise per
week
<150 144 77.0 70 60.0
≥150 43 23.0 46 40.0
DINE score (saturated fat)
≤40 137 74.0 91 79.8
>40 49 26.0 23 20.2
AUDIT hazardous drinking score
>7 96 48.2 33 28.7
≤7 102 51.8 82 71.3
Current smoker?
Yes 139 76.8 66 73.3
HbA1c, haemoglobin A1c; IPAQ, International Physical Activity Questionnaire; DINE,
Dietary Instrument for Nutrition Education; AUDIT, Alcohol Use Disorders Identification
Test.
a. Men: <1.03 mmol/L; women: <1.29 mmol/L.
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Fig. 1 Rates of identified cardiometabolic risk at each time point.
(a) Central obesity; (b) low high-density lipoprotein (HDL); (c) raised haemoglobin HbA1c; (d) raised blood pressure; and (e) raised triglycerides.
Table 3 Effects of gender and ethnicity
Men Women
Difference
by gender White Other ethnicity
Difference
by ethnicity
Body mass index (kg/m2), mean (s.d.)
Baseline (n = 180) 25.5 (4.6) 26.0 (6.3) −0.5 25.7 (5.4) 25.7 (5.1) 0.0
12 months (n = 93) 27.2 (5.3) 26.6 (5.4) 0.6 26.9 (5.6) 27.0 (5.1) −0.1
Total cholesterol (mmol/L), mean (s.d.)
Baseline (n = 186) 4.81 (1.05) 4.80 (0.83) 0.01 4.93 (1.12) 4.70 (0.82) 0.23
12 months (n = 114) 4.81 (1.22) 4.82 (0.92) −0.01 5.05 (1.36) 4.62 (0.80) 0.43
HbA1c (mmol/mol), median (upper and lower quartiles)
Baseline (n = 167) 34.4 (32.2–37.7) 33.3 (32.2–35.5) 1.1 34.4 (32.2–36.6) 34.4 (32.8–37.7) 0.0
12 months (n = 93) 36.6 (34.4–39.9) 36.6 (33.3–38.8) 0.0 34.4 (33.3–37.2) 37.7 (35.5–39.9) −3.3
Current smoking (%) (at least once a week)
Baseline (n = 181) 79.8 70.2 9.6 79.2 74.1 5.1
12 months (n = 90) 76.8 67.7 9.1 75. 5 70.7 4.8
Mean waist circumference (cm), mean (s.d.)
Men
Baseline (n = 102) – – – 92.5 (13.6) 88.5 (10.6) 4.0
12 months (n = 66) – – – 97.4 (15.6) 90.1 (11.1) 7.3
Women
Baseline (n = 59) – – – 84.1 (13.3) 93.7 (17.6) −9.6
12 months (n = 44) – – – 86.1 (16.9) 92.9 (16.4) −6.8
s.d., standard deviation; HbA1c, haemoglobin A1c.
Table 4 Association between lifestyle factors at baseline and 12-month change in cardiometabolic risk factors (adjusted for age, gender, ethnicity and
pre-baseline number of days on antipsychotic medication)
Dependent (response) variable/independent
variablea
Coefficient (95% CI)
Baseline DINE
fat score
Baseline AUDIT
hazardous
drinking score
Baseline number
of h sitting per day
OLZ versus not OLZ
between baseline
and 12 months
12-month change in cholesterol (mmol/mol) 0.008 (−0.088 to 0.025) 0.009 (−0.018 to 0.036) 0.023 (−0.032 to 0.077) −0.247 (−0.738 to 0.245)
12-month change in diastolic blood pressure
(mmHg)
−0.029 (−0.192 to 0.134) 0.045 (−0.252 to 0.341) 0.039 (−0.585 to 0.592) −0.425 (−5.085 to 4.235)
12-month change in HbA1c (mol/mmol) −0.005 (−0.145 to 0.155) 0.137 (−0.049 to 0.324) −0.141 (−0.613 to 0.330) −0.552 (−3.408 to 3.298)
12-month change in waist circumference (cm) 0.034 (−0.167 to 0.235) 0.042 (−0.329 to 0.412) −0.233 (−1.172 to 0.707) 0.326 (−4.712 to 5.364)
12-month change in body mass index (kg/m2) −0.003 (−0.108 to 0.103) 0.019 (−0.143 to 0.181) −0.058 (−0.415 to 0.299) 0.437 (−2.094 to 2.968)
12-month change in high-density lipoproteins
(mmol/L)
−0.001 (−0.008 to 0.007) 0.001 (−0.009 to 0.011) 0.002 (−0.021 to 0.024) −0.084 (−0.259 to 0.090)
12-month change in triglycerides (mmol/L) 0.005 (−0.010 to 0.021) 0.006 (−0.020 to 0.032) 0.010 (−0.053 to 0.072) 0.051 (−0.389 to 0.491)
CI, confidence interval; DINE, Dietary Instrument for Nutrition Education; AUDIT, Alcohol Use Disorders Identification Tes; OLZ, olanzapine; HbA1c, haemoglobin A1c.
a. Separate models used for each association.
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health. The diverse nature of the population studied allows explor-
ation of the effect of ethnicity on emergence of cardiometabolic
risk. The use of multiple imputation on a reduced data-set allowed
confidence in the results while retaining generalisability.47
The study must be interpreted taking into account a number of
methodological aspects. Over half our patients required acute in-
patient careat the timeof recruitmentandmanyhad received treatment
for some weeks before being well enough to consent to inclusion. To
minimise this effect and minimise missing data, we therefore sought
permission to use clinical data, where available and comparable, as
well as adjusting for the number of days prescribed antipsychotics
before baseline in our analyses. Also, in follow-up studies there is a
risk that attrition may not be random. Therefore, considerable efforts
were made to minimise loss to follow-up with contact made with
81% (217/268) of the then eligible participants at 12 months, although
73 participants declined 12-month follow-up. There was recompense
for time but no financial incentivisation to remain in the study.
Analysis showed no differences in baseline demographic or clinical
attributes between completers and non-completers. The supplemen-
tary tables include a descriptive table of complete paired measures.
We also note that although 89 people were prescribed olanzapine at
baseline, some did not sustain that prescription throughout the study
period, possibly because of emergent metabolic effects. Finally, the
number of statistical tests carriedoutwas reasonably large and although
we took a more conservative threshold of statistical significance, we
cannot completely discount the possibility of type I errors.
In conclusion, our results identify that cardiometabolic risk
factors are already pronounced in those presenting to FEP services
and worsen over the first year under standard care. No baseline
behaviour predicted risk of worsening cardiometabolic parameters,
but a greater degree of emergent glucose dysregulation was observed
in those from BME groups.
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